Skip to main content
RARE logo

RARE · Ultragenyx Pharmaceutical Inc. · Webcasts, Transcripts & Audio

Track RARE — free
$16.08 -0.19 (-1.17%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Market Cap
$1.64B
Shares
101.92M
Volume · Nov 13 1.68M Avg daily vol (3M) 4.49M

Ultragenyx Pharmaceutical Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Ultragenyx Pharmaceutical Inc. (RARE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-03
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript
Positive tone Path to profitability and cost reduction Two gene therapy launches Citruzumab for osteogenesis imperfecta
Revenue
$173.00M
▲ 8.1% YoY
Diluted EPS
$-1.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-17
Ultragenyx Pharmaceutical Inc. (RARE) September 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-19
Ultragenyx Pharmaceutical Inc. (RARE) August 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call
Positive tone Angelman syndrome Phase III (GTX102) endpoints and design DTX401 regulatory progress UX143 (citruzumab) for osteogenesis imperfecta
Revenue
$214.00M
▲ 28.1% YoY
Diluted EPS
$-0.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Ultragenyx Pharmaceutical Inc. (RARE) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Ultragenyx Pharmaceutical Inc. (RARE) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Confident tone GTX-102 in Angelman syndrome Phase 3 program Global commercial expansion Long-term GTX-102 durability and safety
Revenue
$136.00M
▼ 2.2% YoY
Diluted EPS
$-1.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-10
Ultragenyx Pharmaceutical Inc. (RARE) March 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-12
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
Positive tone UX-111 MPS-3A program and FDA resubmission Regulatory environment / FDA biomarker scrutiny 2026 financial guidance
Revenue
$207.00M*
▲ 25.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
Confident tone Crysvita commercial performance and royalty financing DTX401 in GSDIa clinical results Other commercial products (Dojolvi, Evkeeza, Mepsevii)
Revenue
$160.00M
▲ 14.7% YoY
Diluted EPS
$-1.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript
Confident tone Setrusumab (UX143) Phase III Commercial Revenue Growth Crysvita Commercial Performance
Revenue
$167.00M
▲ 13.6% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call
Confident tone Gene therapy franchise (Sanfilippo and GSD1A) launches Path to profitability in 2027 and cash management Citruzumab regulatory path forward
Revenue
$139.00M
▲ 27.7% YoY
Diluted EPS
$-1.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Confident tone UX143 / setrusumab osteogenesis imperfecta (OI) Phase 3 GSDIa gene therapy BLA filing Revenue and commercial growth
Revenue
$164.65M*
▲ 29.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
Confident tone Setrusumab / UX-143 for osteogenesis imperfecta (OI) International expansion (LatAm, EMEA, Japan) DTX401 for GSDIa gene therapy
Revenue
$139.49M
▲ 42.3% YoY
Diluted EPS
$-1.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript
Confident tone Late-stage clinical pipeline readouts Setrusumab / Orbit Phase 3 trial Crysvita commercial momentum
Revenue
$147.03M
▲ 35.7% YoY
Diluted EPS
$-1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2024 Earnings Call Transcript
Confident tone GTX-102 Angelman Syndrome Setrusumab Osteogenesis Imperfecta (Orbit/Cosmic) Regulatory Engagement / FDA Endpoints
Revenue
$108.83M
▲ 8.3% YoY
Diluted EPS
$-2.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2023 Earnings Call Transcript
Confident tone Crysvita commercial performance GTX-102 Angelman syndrome Dojolvi (LC-FAOD) commercial
Revenue
$127.14M*
▲ 23% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-16
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2023 Earnings Call Transcript
Revenue
$98.05M
▲ 8.1% YoY
Diluted EPS
$-2.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2023 Earnings Call Transcript
Revenue
$108.31M
▲ 21.2% YoY
Diluted EPS
$-2.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2023 Earnings Call Transcript
Revenue
$100.50M
▲ 25.7% YoY
Diluted EPS
$-2.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2022 Earnings Call Transcript
Revenue
$103.35M*
▲ 23.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2022 Earnings Call Transcript
Revenue
$90.70M
▲ 11.1% YoY
Diluted EPS
$-3.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2022 Earnings Call Transcript
Revenue
$89.34M
▲ 2.7% YoY
Diluted EPS
$-2.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2022 Earnings Call Transcript
Revenue
$79.94M
▼ 19.6% YoY
Diluted EPS
$-2.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2021 Earnings Call Transcript
Revenue
$83.39M*
▼ 8.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2021 Earnings Call Transcript
Revenue
$81.65M
▲ 0.2% YoY
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-02
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2021 Earnings Call Transcript
Revenue
$86.97M
▲ 40.9% YoY
Diluted EPS
$-1.81
▼ 541.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2021 Earnings Call Transcript
Revenue
$99.39M
▲ 173.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2020 Earnings Call Transcript
Revenue
$91.54M
▲ 157.2% YoY
Diluted EPS
$-0.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-27
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2020 Earnings Call Transcript
Revenue
$81.47M
▲ 215.8% YoY
Diluted EPS
$-1.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2020 Earnings Call Transcript
Revenue
$61.71M
▲ 155.5% YoY
Diluted EPS
$0.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2020 Earnings Call Transcript
Revenue
$36.31M
▲ 99.8% YoY
Diluted EPS
$-2.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2019 Earnings Call
Revenue
$35.59M
▲ 118.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–33 of 33 webcasts
Key facts CIK 1515673 CUSIP 90400D108 13F (30d) 197 filings 177 filers Visit website Investor relations